Celgene President and COO Departs; Leadership Team Structure Modified
Celgene announced on April 2, 2018 that Scott A. Smith, President and Chief Operating Officer (COO), is leaving the company effective immediately. His primary responsibilities will be assumed by Chairman and Chief Executive Officer Mark J. Alles.
Smith served as President and COO starting in April 2017. He joined Celgene in 2008 and held several senior positions, including as Vice President, Global Marketing, Inflammation and Immunology, Senior Vice President, Global Head of Inflammation and Immunology, and President, Global Inflammation and Immunology.
The change in leadership is part of Celgene’s move to modify its executive team structure. In addition to existing responsibilities, Alles will be responsible for strategic leadership of Celgene’s Global Hematology and Oncology franchise, Global Inflammation and Immunology franchise, manufacturing, regulatory, and clinical development. The following members of the Celgene Executive Committee will report directly to Alles: Nadim Ahmed, President, Global Hematology and Oncology; Terrie Curran, President, Global Inflammation and Immunology; Jay Backstrom, MD, Chief Medical Officer and Head of Global Regulatory Affairs; and Joanne Beck, PhD., Executive Vice President, Global Pharmaceutical Development and Operations.